Overview

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Status:
RECRUITING
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Dexamethasone
fludarabine